That's right, but we're the first to sort of couple these things together, and the results are preliminary. As you know, the best work that's done by scientists is that which is peer reviewed. We should get this published, and then we should move this into the commercial market.
Michael Hayden, the geneticist, and I were just awarded a commercialization grant from Genome British Columbia. We plan on bringing one of those three discoveries to the commercial market. I'm particularly interested in doing that quickly, for a couple of reasons. It's mostly because it can help to further endow the work we're doing. Doing this kind of work and getting the kinds of funds you need to run a national surveillance system is very difficult for an academic, and it requires continuous care and feeding. At the end of my three-year funding stint, which ends in December, I will have no funding. People begin leaving surveillance positions six to eight months before the funding runs out, to find other positions. It's critical that we endow this work so that we can continue to make it grow.